Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma.
Vining CC, Hsu PJ, Miller A, Olson DJ, Gajewski TF, Pytel P, Bauer BS, Millis MJ, Roggin KK. Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma. Melanoma Res. 2021 02 01; 31(1):92-97.
PMID: 33323721
Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma.
Vining CC, Hsu PJ, Miller A, Olson DJ, Gajewski TF, Pytel P, Bauer BS, Millis MJ, Roggin KK. Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma. Melanoma Res. 2020 Dec 14; Publish Ahead of Print.
PMID: 33323721
Sensitive detection and quantification of SARS-CoV-2 in saliva.
Abasiyanik MF, Flood B, Lin J, Ozcan S, Rouhani SJ, Pyzer A, Trujillo J, Zhen C, Wu P, Jumic S, Wang A, Gajewski TF, Wang P, Hartley M, Ameti B, Niemiec R, Fernando M, Aydogan B, Bethel C, Matushek S, Beavis KG, Agrawal N, Segal J, Tay S, Izumchenko E. Sensitive detection and quantification of SARS-CoV-2 in saliva. medRxiv. 2020 Dec 07.
PMID: 33330880
Cancer and the Microbiome: Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy.
Matson V, Chervin CS, Gajewski TF. Cancer and the Microbiome: Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology. 2020 Nov 28.
PMID: 33253684
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol AK, Weiss A, Danahey K, Karrison TG, Edens CC, Bauer Ventura I, Pettit NN, Patel BK, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2020 Nov 18.
PMID: 33210302
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 Dec 15; 26(24):6437-6444.
PMID: 33028595
Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion.
Koss B, Shields BD, Taylor EM, Storey AJ, Byrum SD, Gies AJ, Washam CL, Choudhury SR, Hyun Ahn J, Uryu H, Williams JB, Krager KJ, Chiang TC, Mackintosh SG, Edmondson RD, Aykin-Burns N, Gajewski TF, Wang GG, Tackett AJ. Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion. Cancer Res. 2020 Nov 01; 80(21):4707-4719.
PMID: 33004350
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).
Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, Luke JJ, Osman I, Postow MA, Sullivan RJ, Taube JM, Trinchieri G, Zarour HM, Caracò C, Thurin M. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). J Transl Med. 2020 09 07; 18(1):346.
PMID: 32894202
Immunotherapy with a sting.
Gajewski TF, Higgs EF. Immunotherapy with a sting. Science. 2020 08 21; 369(6506):921-922.
PMID: 32820113
cDC1 dysregulation in cancer: An opportunity for intervention.
Gajewski TF, Cron KR. cDC1 dysregulation in cancer: An opportunity for intervention. J Exp Med. 2020 Aug 03; 217(8).
PMID: 32697286